The Life Sciences team advised Amylyx Pharmaceuticals, Inc. (“Amylyx”) (Nasdaq: AMLX) on an upsized underwritten public offering of 16,203,500 shares of its common stock at a public offering price of $35.50 per share, which included the full exercise by the underwriters of their option to purchase an additional 2,113,500 shares. The gross proceeds from the offering were approximately $575.2 million before deducting underwriting discounts and commissions and offering expenses. All of the shares were offered by Amylyx.
Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital acted as joint bookrunning managers for the offering.
Amylyx’s mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, Amylyx sees opportunities and pursues them with urgency, rigorous science, and unwavering commitment to the communities it serves. Amylyx is currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which it believes it can make the greatest impact. Amylyx is headquartered in Cambridge, Massachusetts.
The Goodwin team was led by Ben Marsh, Janet Hsueh, Lauren Zhang, Haylee Brown, and Anderson Riddick, and included Julie Tibbets, Dan Karelitz, and Maggie Wong.
For more information on the deal, please read the pricing press release.